Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49

Peter K. Leichner, Gamal Akabani, David Colcher, Katherine A. Harrison, William G. Hawkins, Miriam Eckblade, Janina Baranowska-Kortylewicz, Samuel C. Augustine, James Wisecarver, Margaret A. Tempero

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The objective of this work was to develop patient-specific dosimetry for patients with metastatic gastrointestinal tract cancers who received 111In-CC49 IgG for imaging before therapy with 90Y-CC49 IgG. Methods: Whole-body imaging of 12 patients, who received 111-185 MBq (3-5 mCi) of 111In-CC49, commenced in <2 hr postinfusion and was continued daily for 4-5 days. SPECT data were acquired at 24 and 72 hr to determine the range of 111In-CC49 activity concentrations in tumors and normal organs. Time- activity curves were generated from the image data and scaled from 111In- CC49 to 90Y-CC49 for dosimetric purposes. Absorbed-dose calculations for 90Y-CC49 included the mean and range in tumor and normal organs. Computed 90Y-CC49 activity concentrations were compared with measurements on 10 needle biopsies of normal liver and tour tumor biopsies. Results: In 9 of 10 normal liver samples, the range of computed 90Y-CC49 activity concentrations bracketed measured values. This was also the case for 3 of 4 tumor biopsies. Absorbed-dose calculations for 90Y-CC49 were based on patients' images and activities in tissue samples and, hence, were patient- specific. Conclusion: For the radiolabeled antibody preparations used in this study, quantitative imaging of 111In-CC49 provided the data required for 90Y-0C49 dosimetry. The range of activities in patients' SPECT images was determined for a meaningful comparison of measured and computed values. Knowledge of activity distributions in tumors and normal organs was essential for computing mean values and ranges of absorbed dose and provided a more complete description of the absorbed dose from 90Y-CC49 than was possible with planar methods.

Original languageEnglish
Pages (from-to)512-516
Number of pages5
JournalJournal of Nuclear Medicine
Volume38
Issue number4
StatePublished - 1997
Externally publishedYes

Fingerprint

Yttrium
Indium
Monoclonal Antibodies
Neoplasms
Single-Photon Emission-Computed Tomography
Immunoglobulin G
Biopsy
Whole Body Imaging
Gastrointestinal Neoplasms
Liver
Needle Biopsy
Antibodies

All Science Journal Classification (ASJC) codes

  • Radiological and Ultrasound Technology

Cite this

Leichner, P. K., Akabani, G., Colcher, D., Harrison, K. A., Hawkins, W. G., Eckblade, M., ... Tempero, M. A. (1997). Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. Journal of Nuclear Medicine, 38(4), 512-516.

Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. / Leichner, Peter K.; Akabani, Gamal; Colcher, David; Harrison, Katherine A.; Hawkins, William G.; Eckblade, Miriam; Baranowska-Kortylewicz, Janina; Augustine, Samuel C.; Wisecarver, James; Tempero, Margaret A.

In: Journal of Nuclear Medicine, Vol. 38, No. 4, 1997, p. 512-516.

Research output: Contribution to journalArticle

Leichner, PK, Akabani, G, Colcher, D, Harrison, KA, Hawkins, WG, Eckblade, M, Baranowska-Kortylewicz, J, Augustine, SC, Wisecarver, J & Tempero, MA 1997, 'Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49', Journal of Nuclear Medicine, vol. 38, no. 4, pp. 512-516.
Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M et al. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. Journal of Nuclear Medicine. 1997;38(4):512-516.
Leichner, Peter K. ; Akabani, Gamal ; Colcher, David ; Harrison, Katherine A. ; Hawkins, William G. ; Eckblade, Miriam ; Baranowska-Kortylewicz, Janina ; Augustine, Samuel C. ; Wisecarver, James ; Tempero, Margaret A. / Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. In: Journal of Nuclear Medicine. 1997 ; Vol. 38, No. 4. pp. 512-516.
@article{bf963b8893f342118a6408a2848db2f1,
title = "Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49",
abstract = "The objective of this work was to develop patient-specific dosimetry for patients with metastatic gastrointestinal tract cancers who received 111In-CC49 IgG for imaging before therapy with 90Y-CC49 IgG. Methods: Whole-body imaging of 12 patients, who received 111-185 MBq (3-5 mCi) of 111In-CC49, commenced in <2 hr postinfusion and was continued daily for 4-5 days. SPECT data were acquired at 24 and 72 hr to determine the range of 111In-CC49 activity concentrations in tumors and normal organs. Time- activity curves were generated from the image data and scaled from 111In- CC49 to 90Y-CC49 for dosimetric purposes. Absorbed-dose calculations for 90Y-CC49 included the mean and range in tumor and normal organs. Computed 90Y-CC49 activity concentrations were compared with measurements on 10 needle biopsies of normal liver and tour tumor biopsies. Results: In 9 of 10 normal liver samples, the range of computed 90Y-CC49 activity concentrations bracketed measured values. This was also the case for 3 of 4 tumor biopsies. Absorbed-dose calculations for 90Y-CC49 were based on patients' images and activities in tissue samples and, hence, were patient- specific. Conclusion: For the radiolabeled antibody preparations used in this study, quantitative imaging of 111In-CC49 provided the data required for 90Y-0C49 dosimetry. The range of activities in patients' SPECT images was determined for a meaningful comparison of measured and computed values. Knowledge of activity distributions in tumors and normal organs was essential for computing mean values and ranges of absorbed dose and provided a more complete description of the absorbed dose from 90Y-CC49 than was possible with planar methods.",
author = "Leichner, {Peter K.} and Gamal Akabani and David Colcher and Harrison, {Katherine A.} and Hawkins, {William G.} and Miriam Eckblade and Janina Baranowska-Kortylewicz and Augustine, {Samuel C.} and James Wisecarver and Tempero, {Margaret A.}",
year = "1997",
language = "English",
volume = "38",
pages = "512--516",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49

AU - Leichner, Peter K.

AU - Akabani, Gamal

AU - Colcher, David

AU - Harrison, Katherine A.

AU - Hawkins, William G.

AU - Eckblade, Miriam

AU - Baranowska-Kortylewicz, Janina

AU - Augustine, Samuel C.

AU - Wisecarver, James

AU - Tempero, Margaret A.

PY - 1997

Y1 - 1997

N2 - The objective of this work was to develop patient-specific dosimetry for patients with metastatic gastrointestinal tract cancers who received 111In-CC49 IgG for imaging before therapy with 90Y-CC49 IgG. Methods: Whole-body imaging of 12 patients, who received 111-185 MBq (3-5 mCi) of 111In-CC49, commenced in <2 hr postinfusion and was continued daily for 4-5 days. SPECT data were acquired at 24 and 72 hr to determine the range of 111In-CC49 activity concentrations in tumors and normal organs. Time- activity curves were generated from the image data and scaled from 111In- CC49 to 90Y-CC49 for dosimetric purposes. Absorbed-dose calculations for 90Y-CC49 included the mean and range in tumor and normal organs. Computed 90Y-CC49 activity concentrations were compared with measurements on 10 needle biopsies of normal liver and tour tumor biopsies. Results: In 9 of 10 normal liver samples, the range of computed 90Y-CC49 activity concentrations bracketed measured values. This was also the case for 3 of 4 tumor biopsies. Absorbed-dose calculations for 90Y-CC49 were based on patients' images and activities in tissue samples and, hence, were patient- specific. Conclusion: For the radiolabeled antibody preparations used in this study, quantitative imaging of 111In-CC49 provided the data required for 90Y-0C49 dosimetry. The range of activities in patients' SPECT images was determined for a meaningful comparison of measured and computed values. Knowledge of activity distributions in tumors and normal organs was essential for computing mean values and ranges of absorbed dose and provided a more complete description of the absorbed dose from 90Y-CC49 than was possible with planar methods.

AB - The objective of this work was to develop patient-specific dosimetry for patients with metastatic gastrointestinal tract cancers who received 111In-CC49 IgG for imaging before therapy with 90Y-CC49 IgG. Methods: Whole-body imaging of 12 patients, who received 111-185 MBq (3-5 mCi) of 111In-CC49, commenced in <2 hr postinfusion and was continued daily for 4-5 days. SPECT data were acquired at 24 and 72 hr to determine the range of 111In-CC49 activity concentrations in tumors and normal organs. Time- activity curves were generated from the image data and scaled from 111In- CC49 to 90Y-CC49 for dosimetric purposes. Absorbed-dose calculations for 90Y-CC49 included the mean and range in tumor and normal organs. Computed 90Y-CC49 activity concentrations were compared with measurements on 10 needle biopsies of normal liver and tour tumor biopsies. Results: In 9 of 10 normal liver samples, the range of computed 90Y-CC49 activity concentrations bracketed measured values. This was also the case for 3 of 4 tumor biopsies. Absorbed-dose calculations for 90Y-CC49 were based on patients' images and activities in tissue samples and, hence, were patient- specific. Conclusion: For the radiolabeled antibody preparations used in this study, quantitative imaging of 111In-CC49 provided the data required for 90Y-0C49 dosimetry. The range of activities in patients' SPECT images was determined for a meaningful comparison of measured and computed values. Knowledge of activity distributions in tumors and normal organs was essential for computing mean values and ranges of absorbed dose and provided a more complete description of the absorbed dose from 90Y-CC49 than was possible with planar methods.

UR - http://www.scopus.com/inward/record.url?scp=0030946346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030946346&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 512

EP - 516

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4

ER -